ClinicalTrials.gg
WithdrawnNCT07345845Updated Oct 29, 2026

MR and Inflammation After Preeclampsia

An Early Phase 1 interventional study of Eplerenone in Preeclampsia and Preeclampsia Postpartum, sponsored by Anna Stanhewicz, PhD. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science

How we know

Why this study was withdrawn
Trainee project; study never initiated
Updated Oct 29, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.

Enrollment
149th of 161
0 · median 89
Started
2025
with 12 others
Phase 1
21 of 230
6 open now
Registered
212th of 230
by date
Lead sponsor
8 of 230
Anna Stanhewicz, PhD

Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 149th largest by enrollment of the 161 interventional ones that give a count, is one of 13 that started in 2025, is one of 21 in phase 1, and was the 212th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Pre-Eclampsia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this investigation is to examine the role of inappropriate mineralocorticoid receptor activation in endothelial dysfunction and vascular inflammation in otherwise healthy women with a history of preeclampsia. The main questions it aims to answer are:

  1. Does overactivation of the mineralocorticoid receptor contribute to reduced endothelial function in women who had preeclampsia?
  2. To what extent does the mineralocorticoid receptor mediated exaggerated production of inflammatory cytokines in immune cells from women who had preeclampsia?

Participants will visit the research laboratory for 2 experimental visits:

  • Visit 1: Skin blood flow will be measured using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) to examine blood vessels in a nickel-sized area of the skin.
  • Visit 2: Endothelial cells will be collected from an antecubital vein.
03

Conditions studied

  • Preeclampsia
  • Preeclampsia Postpartum

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women who had preeclampsia and women who did not have preeclampsia
  • 12 weeks to 5 years postpartum
  • 18-45 years old

Exclusion criteria

Exclusion Criteria:

  • history of hypertension or metabolic disease before pregnancy
  • history of gestational diabetes
  • history of gestational hypertension without preeclampsia
  • skin diseases
  • current tobacco use
  • current antihypertensive medication
  • statin or other cholesterol-lowering medication
  • currently pregnant
  • less than 18.5 kg/m2
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergy to study drugs or salt-supplement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Assessment of microvascular function

    The investigators use intradermal microdialysis to deliver eplerenone and L-NAME to the cutaneous microvasculature

    Drug: Eplerenone

Interventions

  • Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response

06

What researchers measure

Primary outcomes

  1. Change in microvascular endothelial function following local eplerenone treatment compared to placebo treatment measured by laser-Doppler flowmetry

    Cutaneous vascular vasodilator response (cutaneous conductance; %max) to local heating of the skin; intradermal microdialysis for the local delivery of eplerenone compared to control (Ringer's solution), followed by L-NAME infusion to quantify NO-dependent response

    Time frame: post 1 hour of skin perfusion

Secondary outcomes

  1. Mineralocorticoid receptor expression in endothelial cells

    The investigators will quantify expression of the mineralocorticoid receptor in biopsied endothelial cells.

    Time frame: a total of 1 time during the study, within ~4 weeks following enrollment

  2. Inflammatory response from isolated immune cells

    The investigators will measure inflammatory responses, assessed as inflammatory cytokine release following activation of immune cells in the presence and absence of eplerenone treatment. Cells are collected from a blood draw and treated with eplerenone in a cell culture environment (ex vivo treatment).

    Time frame: from a blood draw collected at the start of the experimental visit

07

Study locations

1 site
  • University of Iowa
    Iowa City, Iowa 52242, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 16, 2026
StartActual
Dec 17, 2025
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Withdrawn Trainee project; study never initiated
changed Oct 29, 2026
Enrollment
40 (estimated)→0 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Withdrawn
    Why stopped Trainee project; study never initiated
    Enrollment 40 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07345845
Lead sponsor
Anna Stanhewicz, PhD
Responsible party
Anna Stanhewicz, PhD (Associate Professor, University of Iowa) — Sponsor-investigator
First posted
Jan 16, 2026
Start date
Dec 17, 2025
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Anna Reid-Stanhewicz, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eplerenone

Start the discussion